니콜라스(닉) 오키프는 인수합병(M&A) 및 기업·증권법 분야에서 약 30년의 경력을 보유하고 있으며, 특히 매수 측 및 매도 측 업무와 인수 방어 전략에 중점을 두고 국내 및 국경 간 거래를 다뤄왔습니다. 그는 기술, 기술 서비스, 핀테크, 헬스케어, 생명과학 산업 전반에 걸쳐 상장·비상장 기업 및 투자 펀드와 폭넓게 협력해 왔습니다.
Nick also advises emerging growth and mature issuers, entrepreneurs, executives and board members with respect to contested situations, corporate governance matters, federal and state securities law matters, and securities transactions. Having spent three years working in the Middle East, O’Keefe possesses deep knowledge of emerging markets.
Representative Transactional Experience
혁신적인 기술
- Represented Advanced Micro Devices, Inc., a NASDAQ-listed semiconductor company, in the cash/stock acquisition of ATI Technologies, Inc., a TSX and NASDAQ-listed graphics semiconductor company, and in the acquisition of Nod.ai, an open-source AI software company.*
- Represented City National Bank with respect to multiple fintech acquisitions and joint venture transactions.*
- Represented Cliosoft, Inc., an EDA company, in its sale to Keysight Technologies, Inc.*
- Represented Cognizant Technology Services Corporation, a Fortune 200 tech services company, with respect to multiple acquisitions.*
- Represented Contactual, Inc., a cloud-based telemarketing company, in the cash sale of the company to 8X8, Inc.*
- Represented Digital Air Strike, a private digital marketing company, in a merger with ResponseLogix, Inc.*
- Represented Eximius Design, LLC, a semiconductor design company, in its sale to Wipro.*
- Represented Genstar Capital in the simultaneous acquisitions of a public company and a private company in the health care technology services industries.*
- Represented Honeywell International, Inc., an integrated operating company serving a broad range of industries and geographies around the world, in the acquisition of Compressor Controls Corporation.*
- Represented Hutchison Whampoa Limited, a Chinese telecommunications company, in the cash acquisition of the mediator assets of Luxxon Corporation.*
- Represented IMImobile plc, an AIM-listed company, in the acquisition of 3Cinteractive Corp., a U.S. technology company.*
- Represented Indie Semiconductor, Inc., a NASDAQ-listed semiconductor company, in an acquisition transaction.*
- Represented KKR and Silver Lake in the US$2.7bn LBO acquisition of the semi-conductor products group of Agilent Technologies Inc. to create Avago Technologies Limited.*
- Represented Koninklijke Philips Electronics N.V. in the acquisition of control of two public technology companies.*
- Represented McAfee, Inc., a NASDAQ-listed computer securities solutions company, in the acquisition of a private company.*
- Represented Micrel, Inc., a semiconductor company, in a proxy fight with a hedge fund activist.*
- Represented Microsoft Corporation, a software company, in a joint venture transaction*
- Represented Terayon Communications Systems, Inc., a NASDAQ-listed digital video equipment developer, in the cash sale of the company to Motorola, Inc.*
- Represented Tessera Technologies, Inc., a semiconductor packaging company, in connection with its initial public offering.*
- Represented TrueSpan, Inc., a fabless semiconductor company, in the sale to SiRF Technologies, Inc.*
- Represented VantagePoint Venture Partners, a private equity fund, in the cash acquisition of the worldwide semiconductor assets of the thermal division of ASML, Inc.*
- Represented Verisity Ltd., a NASDAQ-listed EDA company, in the acquisition of a private company, and the subsequent sale of Verisity to Cadence Design Systems, Inc.*
- Represented Xilinx, Inc., a designer and developer of programmable devices and technologies, with respect to multiple acquisitions and corporate venture transactions.*
- Represented Yahoo, Inc. in the acquisition of a Middle Eastern company.*
의료 및 생명 과학
- Represented Aclara Biosciences, Inc., a Nasdaq-listed biotech focused on novel assay solutions for drug discovery and development, in a US$200m stock/CVR merger of equals with Virologics, Inc.*
- Represented Alliance HealthCare Services, Inc., a NYSE-listed medical imaging and radiation therapy company in several private acquisitions and joint ventures, and sale of control transaction.*
- Represented Aviron, a Nasdaq-listed biotech that developed FluMistTM, in general company representation, registered public offerings of convertible notes and common stock, and the US$1.6bn sale of the company to MedImmune, Inc.*
- Represented Boston Scientific Corporation with respect to several corporate venture financings.*
- Represented Genstar Capital, a private equity fund, in the simultaneous acquisitions of a Nasdaq-listed company and a private company in the healthcare technology services industries.*
- Represented Intuitive Surgical, Inc., a Nasdaq-listed company that developed and commercialized robotic surgical devices, in the acquisition of its Korean distributor.*
- Represented Investor group in the purchase of senior subordinated notes and contingent value rights issued by affiliates of Iterum Therapeutics plc, a Nasdaq-listed pharmaceutical company dedicated to developing and commercializing sulopenem.*
- Represented KKR, a private equity fund, in the sale of a controlling interest in Alliance Imaging, Inc. to Oaktree Capital.*
- Represented Koninklijke Philips Electronics N.V. in the acquisition of control of two Nasdaq-listed medical device companies.*
- Represented Kyphon Inc., a Nasdaq-listed medical device company focused on treatment and restoration of spinal anatomy using minimally invasive technology, in several acquisitions and investments, and in the simultaneous US$4bn sale of the company to Medtronic, Inc. and FTC-mandated divestiture.*
- Represented Molina Healthcare, Inc. with respect to various strategic matters.*
- Represented New Leaf Venture Partners, a venture capital fund, with respect to numerous financing transactions involving private offerings and PIPE transactions.*
- Represented Novartis in an investment in a private company, including an option to acquire the company.*
- Represented Nuvelo, Inc., a Nasdaq-listed gene sequencing company, in general company representation, a registered public offering and several PIPE transactions, and a merger of equals with Variagenics, Inc.*
- Represented QLT Inc., a Canadian Nasdaq-listed biotech focused on macular degeneration, in the US$850m cash/stock acquisition of Atrix Laboratories, Inc.*
- Represented Scios, Inc., a Nasdaq-listed biotech focused on novel treatments for cardiovascular and inflammatory diseases, in the US$2.4bn cash sale of the company to Johnson & Johnson.*
- Represented Veeva Systems Inc., a Nasdaq-listed provider of cloud solutions for the life sciences industry, in the cash acquisition of Zinc Ahead, a U.K. company and leading provider of content management solutions for life sciences companies, for approximately US$130m.*
- Represented Verona Pharma plc, an AIM-listed company, in a securities offering into the U.S.*
* Foley에 합류하기 전에 처리된 사항입니다.
Recent Presentations and Publications
- “Is Trump’s FTC the ‘Silver Bullet’ to Cure M&A Ailments?” Agenda (May 2, 2025) (quoted)
- “Stockholders Get ‘Unprecedented’ Power over Boards in Delaware Amendments,” Financial Times Agenda (July 26, 2024) (quoted)
- Co-author, “From Legislation to Innovation: The CHIPS Act and a New Era of Semiconductor Innovation,” Foley’s Innovative Technology Insights (July 23, 2024)
- Co-author, “Delaware Enacts Controversial Market Practice Amendments to Its General Corporation Law,” Foley’s Viewpoints (July 18, 2024)
- Co-author, “U.S. Supreme Court Rules That ‘Pure Omissions’ Are Not Actionable Under Rule 10b-5,” Foley’s Viewpoints (April 23, 2024)
- Co-author, “Significant Recent Decisions Relevant To Private Company M&A,” Foley Ignite (April 16, 2024)
- Co-author, “SEC v Panuwat: The SEC’s Novel “Shadow Trading” Insider Trading Case Goes to Trial,” Foley Ignite (March 13, 2024)
- Co-author, “Palkon v. Maffei: Delaware’s Warning Shot to Controlling Stockholders Seeking to Evade Fiduciary Duties by Reincorporating,” Foley Ignite (March 12, 2024)
- Co-author, “Significant 2022 Decisions Affecting Private Company M&A”, Advisory (February 17, 2023)
- Co-author, “CHIPS Grant Program: Guidance on Submitting Applications”, Advisory (August 26, 2022)
- Co-author, “CHIPS Act Guardrails: Congressional Efforts to Limit Investment in China”, Advisory (July 22, 2022)
- Co-author, “Goldstein v. Denner: Delaware’s Latest Guidance for When a Fund’s Representative on the Board Seeks to Force Through a Quick Sale”, Advisory (June 15, 2022)
- Co-author, “Significant 2021 Decisions Affecting Private Company M&A”, Advisory (February 17, 2022)
- Co-author, “SPAC Redemption Rights—Panacea or Achilles Heel? Delaware Court Denies Defendants’ Motion to Dismiss in MultiPlan Litigation”, Advisory (February 11, 2022)
- Co-author, “Law Firms Respond to Recent Lawsuits Targeting SPACs”, Advisory (September 1, 2021)
- Co-author, “Arnold & Porter Discusses Delaware Case on SPACs and Breaches of Fiduciary Duties”, Columbia Law School’s Blog on Corporations and the Capital Markets (June 15, 2021)
- Co-author, “The Franchi SPAC Complaint: Much to Watch For”, Advisory (June 11, 2021)
- Co-author, “The WeWork Decision and its Implications for Director Email Accounts”, Harvard Law School Forum on Corporate Governance (May 24, 2021)
- Co-author, “2020 in Hindsight: Key Considerations for Directors in 2021”, Harvard Law School Forum on Corporate Governance (April 7, 2021)
- Co-author, “SPAC Transactions: Enforcement and Litigation Risks”, Advisory (April 7, 2021)
- Co-author, “Considerations for Acquisitions and Investments Involving Companies That Have Taken CARES Act Funding”, Coronavirus: Corporate and Finance Advisory (May 27, 2020)
- Presenter, “CARES Act/Federal Reserve Act Section 13(3): Weekly Update 3”, Coronavirus: Financial Services Webinar (May 22, 2020)
- Co-author, “Significant 2019 Decisions Affecting Private Company M&A”, Newsletter (February 5, 2020)
- Presenter, “Top 10 Tips for Effective Board Oversight of M&A Transactions”, Seminar, Palo Alto, CA (January 29, 2020)
니콜라스 오키프의 DExit 운동에 관한 글
폴리 앤 라드너 LLP의 파트너 니콜라스 오키프는 파이낸셜 타임스 산하 간행물인 '아젠다'에서, 델라웨어 주 대법원이 최근 일론 머스크의 성과급을 복원하기로 한 결정에서 배울 점이 있는지 검토했다.
/Passle/6719610cd4590e288ff40ff4/SearchServiceImages/2025-12-18-16-16-07-966-694428c75555b955e43968a7.jpg)
Semiconductors Podcast - Data Centers: The Role of AI and Semiconductors in Transforming an Industry
데이터 센터: 산업 변혁에서 AI와 반도체의 역할 핵심 요약 AI는 데이터 센터에 대한 전례 없는 수요를 촉진하고 있습니다...
니콜라스 오키프, 델라웨어의 M&A 소송 급증에 대한 평가
폴리 앤 라드너 LLP의 파트너인 니콜라스 오키프는 파이낸셜 타임즈에 게재된 어젠다 기사 "M&A 소송 합의가 델라웨어에서 크게 증가하고 있다"에서 델라웨어의 인수합병 소송 활동의 증가에 대해 언급했습니다.
니콜라스 오키프, '황금 주식'에 대한 외국인 투자자의 반응을 평가하다
폴리 앤 라드너 LLP의 파트너인 니콜라스 오키프는 파이낸셜 타임즈 간행물인 fDi 인텔리전스에서 트럼프 행정부의 민간 기업 지분 인수에 대해 평가했습니다.
폴리, 아티스트와 음반사를 위한 음악 보호를 목표로 인공지능 기반 불법 복제 방지 연구소 출범에 사운드패트롤 대리
폴리 앤드 라드너 LLP는 AI 스타트업 사운드패트롤의 음악 기술 및 AI 기반 불법 복제 방지 연구실 설립과 자금 조달을 대리했습니다.
/Passle/63109459f636e905f41c4854/MediaLibrary/Images/2025-09-16-22-33-29-710-68c9e5b98206a7b639846e24.png)
김 대 펨토메트릭스 사건: 델라웨어 주 법원, 소수 주주에게 불리하게 악용될 수 있는 일반 주주 협약 조항의 허점을 부각
김 대 펨토메트릭스 사건은 회사와 대주주가 계약을 수정할 수 있도록 허용한 투표 계약의 일반적인 공백을 다룬다...